Kelly Stratton, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Sanofi Genzyme Corp.
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (General Urology)
    Ineligible company:
    Bayer Corporation
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (General Urology)
    Ineligible company:
    MJH Life Sciences
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Oakstone
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Janssen Pharmaceuticals
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    MJH Life Sciences
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (General Urology)
    Ineligible company:
    Ebix
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    Myovant Sciences
    Date added:
    Date updated:
    07/25/2024
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Specialty Not Specified)
    Ineligible company:
    Roche/Genentech
    Date added:
    Date updated:
    07/25/2024

Pages

Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion: A Virtual Course (2022)